27494909|t|Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi
27494909|a|No data are available on bone metabolism in infants exposed to tenofovir during breastfeeding. We investigated bone metabolism markers in the first year of life in infants from mothers who received tenofovir, lamivudine and efavirenz during pregnancy and 12 months of breastfeeding in a national Option B+ programme in Malawi. Serum samples collected at 6 and 12 months in tenofovir - exposed infants and in a small sample of tenofovir - unexposed infants from the same clinical centre were analysed in batches for levels of bone-specific alkaline phosphatase (BAP; marker of bone formation) and of C-terminal telopeptide of type I collagen (CTX; marker of bone resorption). Overall, 136 tenofovir - exposed infants were evaluated. No infant had at either timepoint CTX values above the upper normal limit, while most of them had at 6 and 12 months levels of BAP above the upper normal limit for the age range. Levels of bone markers showed no differences by gender and no association with growth parameters. Tenofovir - unexposed and - exposed children had similar mean levels of bone markers at 6 months (CTX: 0.62 versus 0.55 ng/mL, P = 0.122; BAP: 384 versus 362 U/L, P = 0.631). No significant association between treatment with tenofovir and CTX or BAP levels was found. The high levels of BAP, coupled to the normal levels observed for CTX, might reflect primarily skeletal growth. Potential negative effects of prolonged exposure to tenofovir through breastfeeding cannot however be excluded and longitudinal studies that evaluate bone mineralization status in children enrolled in Option B+ programmes are warranted.
27494909	0	6	Levels	T080	C0441889
27494909	10	14	bone	T024	C0391978
27494909	15	22	markers	T201	C0005516
27494909	28	38	population	T098	C1257890
27494909	42	57	infants exposed	T101	C0683996
27494909	58	66	in utero	T100	C1708480
27494909	78	91	breastfeeding	T040	C0006147
27494909	95	104	tenofovir	T114,T121	C0384228
27494909	115	134	Option B+ programme	T058	C1254363
27494909	138	144	Malawi	T083	C0024548
27494909	145	152	No data	T080	C1546437
27494909	170	185	bone metabolism	T042	C0596204
27494909	189	204	infants exposed	T101	C0683996
27494909	208	217	tenofovir	T114,T121	C0384228
27494909	225	238	breastfeeding	T040	C0006147
27494909	243	255	investigated	T169	C1292732
27494909	256	271	bone metabolism	T042	C0596204
27494909	272	279	markers	T201	C0005516
27494909	293	297	year	T079	C0439234
27494909	301	305	life	T078	C0376558
27494909	309	316	infants	T100	C0021270
27494909	322	329	mothers	T099	C0026591
27494909	343	352	tenofovir	T114,T121	C0384228
27494909	354	364	lamivudine	T114,T121	C0209738
27494909	369	378	efavirenz	T109,T121	C0674428
27494909	386	395	pregnancy	T040	C0032961
27494909	403	409	months	T079	C0439231
27494909	413	426	breastfeeding	T040	C0006147
27494909	432	460	national Option B+ programme	T058	C1254363
27494909	464	470	Malawi	T083	C0024548
27494909	472	477	Serum	T031	C0229671
27494909	478	485	samples	T167	C0370003
27494909	508	514	months	T079	C0439231
27494909	518	527	tenofovir	T114,T121	C0384228
27494909	530	545	exposed infants	T101	C0683996
27494909	555	567	small sample	T081	C0242618
27494909	571	580	tenofovir	T114,T121	C0384228
27494909	583	600	unexposed infants	T098	C2349018
27494909	615	630	clinical centre	T073,T093	C0442592
27494909	636	644	analysed	T062	C0936012
27494909	648	655	batches	T081	C1948031
27494909	660	666	levels	T080	C0441889
27494909	670	704	bone-specific alkaline phosphatase	T116,T126	C0312399
27494909	706	709	BAP	T116,T126	C0312399
27494909	711	717	marker	T201	C0005516
27494909	721	735	bone formation	T042	C0029433
27494909	744	785	C-terminal telopeptide of type I collagen	T116	C0631180
27494909	787	790	CTX	T116	C0631180
27494909	792	798	marker	T201	C0005516
27494909	802	817	bone resorption	T042	C0005974
27494909	833	842	tenofovir	T114,T121	C0384228
27494909	845	860	exposed infants	T098	C2348484
27494909	866	875	evaluated	T058	C0220825
27494909	880	886	infant	T100	C0021270
27494909	901	910	timepoint	T079	C2348792
27494909	911	914	CTX	T116	C0631180
27494909	915	921	values	T080	C0042295
27494909	932	950	upper normal limit	T081	C1519815
27494909	987	993	months	T079	C0439231
27494909	994	1000	levels	T080	C0441889
27494909	1004	1007	BAP	T116,T126	C0312399
27494909	1018	1036	upper normal limit	T081	C1519815
27494909	1045	1048	age	T032	C0001779
27494909	1049	1054	range	T081	C1514721
27494909	1066	1070	bone	T024	C0391978
27494909	1071	1078	markers	T201	C0005516
27494909	1089	1100	differences	T080	C1705242
27494909	1104	1110	gender	T032	C0079399
27494909	1118	1129	association	T080	C0332281
27494909	1135	1152	growth parameters	T033	C2012645
27494909	1154	1163	Tenofovir	T114,T121	C0384228
27494909	1166	1175	unexposed	T098	C2349018
27494909	1182	1198	exposed children	T098	C2348484
27494909	1203	1210	similar	T080	C2348205
27494909	1211	1215	mean	T081	C0444504
27494909	1216	1222	levels	T080	C0441889
27494909	1226	1230	bone	T024	C0391978
27494909	1231	1238	markers	T201	C0005516
27494909	1244	1250	months	T079	C0439231
27494909	1252	1255	CTX	T116	C0631180
27494909	1292	1295	BAP	T116,T126	C0312399
27494909	1329	1343	No significant	T033	C3694175
27494909	1344	1355	association	T080	C0332281
27494909	1364	1373	treatment	T061	C0087111
27494909	1379	1388	tenofovir	T114,T121	C0384228
27494909	1379	1388	tenofovir	T114,T121	C0384228
27494909	1393	1396	CTX	T116	C0631180
27494909	1400	1403	BAP	T116,T126	C0312399
27494909	1404	1410	levels	T080	C0441889
27494909	1426	1430	high	T080	C0205250
27494909	1431	1437	levels	T080	C0441889
27494909	1441	1444	BAP	T116,T126	C0312399
27494909	1461	1467	normal	T080	C0205307
27494909	1468	1474	levels	T080	C0441889
27494909	1475	1483	observed	T169	C1441672
27494909	1488	1491	CTX	T116	C0631180
27494909	1517	1525	skeletal	T022	C0037253
27494909	1526	1532	growth	T040	C0018270
27494909	1534	1543	Potential	T080	C3245505
27494909	1544	1552	negative	T033	C0205160
27494909	1553	1560	effects	T080	C1280500
27494909	1564	1573	prolonged	T079	C0439590
27494909	1574	1585	exposure to	T080	C0332157
27494909	1586	1595	tenofovir	T114,T121	C0384228
27494909	1586	1595	tenofovir	T114,T121	C0384228
27494909	1604	1617	breastfeeding	T040	C0006147
27494909	1604	1617	breastfeeding	T040	C0006147
27494909	1636	1644	excluded	T052	C2828389
27494909	1649	1669	longitudinal studies	T062	C0023981
27494909	1675	1683	evaluate	T058	C0220825
27494909	1684	1703	bone mineralization	T042	C2350989
27494909	1704	1710	status	T080	C0449438
27494909	1714	1722	children	T100	C0008059
27494909	1735	1755	Option B+ programmes	T058	C1254363